Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Active Ankylosing Spondylitis (MEASURE 1)
NCT01358175Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2011
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of secukinumab in ankylosing spondylitis (AS), sponsored by Novartis. Started Oct 2011; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT01358175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01358175.